KANSAS CITY HEART RHYTHM SYMPOSIUM 2021

August 21-22, 2021

Free Admission

Overland Park Convention Center

Course Director: Dhanunjaya Lakkireddy, MD, FACC, FHRS Kansas City Heart Rhythm Institute, Overland Park, KS





Co-Sponsored by:




www.kchrs.com



KANSAS CITY HEART RHYTHM SYMPOSIUM 2021

August 21-22, 2021 | Overland Park Convention Center | www.kchrs.com

PIONEER IN ELECTROPHYSIOLOGY AWARD RECIPIENT & KEYNOTE SPEAKER



Douglas L. Packer, MD
Professor of Medicine
John M. Nasseff, Sr., Professorship in Cardiology
Director, Interventional Cardiac Electrophysiology Research Laboratories
Mayo Clinic
Rochester, MN

Douglas L. Packer, MD, is a Professor of Medicine, and the John M. Nasseff, Sr., Professor in Cardiovascular Diseases in the Department of Cardiovascular Diseases, Division of Cardiac Electrophysiology, at Mayo Clinic Rochester. He is Director of the Translational Electrophysiology Research Laboratory. Dr. Packer is internationally known in cardiac electrophysiology.

He received the MD degree at the University of Utah and completed an internship, residency and fellowship at Duke University, where he was on staff before coming to Mayo. His honors and awards include the ACC 2019 Distinguished Scientist Award (Translational) (2019), the Distinguished Service Award from Brigham Young University, the Haskel Schiff Award in Internal Medicine from Duke University, the Eric Prystowsky Advocate for Patients Award, and a variety of Visiting Professorship awards.

Dr. Packer is active in the Heart Rhythm Society where he is a past president and member of the Board of Trustees. He is also active in the American Heart Association and the American College of Cardiology. He has served/currently serves on editorial boards for the Circulation Arrhythmia & Electrophysiology, American Heart Journal, the Journal of Cardiovascular Electrophysiology, Heart Rhythm journal, and the (EP) Journal of the American College of Cardiology. He also has served on multiple National Heart, Lung, and Blood Institute work groups on atrial fibrillation, ablation and planning for future NIH studies.

Dr. Packer has been an active teacher and mentor, and also lectures widely on cardiac arrhythmias. He has written or co-authored more than 379 publications. He has lectured extensively in national and international meetings, giving over 1,872 invited lectures in 41 countries. He has served on the executive committee of a number of NIH multicenter randomized clinical trials, Including the MUSTT, SCD-HeFT, and HAT Trials. Dr. Packer is also the International Principal Investigator of the recently reported NIH CABANA Trial. In this capacity he led the consortium of centers directing the trial. He is the PI of the Thermedical VT Needle Electrode study, and on the Executive Committee of the LESS VT Study.

Dr. Packer is a Mayo Clinician Investigator. His translational work focuses on the mechanisms and ablation of atrial fibrillation and other cardiac arrhythmias, autologous fibroblast modulation of electrical impulse propagation in the heart, and the development of carbon particle catheter-free ablation of arrhythmias. His clinical work investigates 4/5 dimensional integrated image-guided ablation, and the development of new energy sources for the modification of cardiac tissue. His work has been funded in part by private foundations, the American Heart Association, and the NIH. A key part of his research is the development of the US Catheter Free Particle Therapy Ablation Program. He is also the PI of the Extracorporeal Particle Therapy Ablation Using Proton and Carbon Beams, that is currently under way. Dr. Packer holds US and European patents in the development of intracardiac ultrasound and 4/5D imaging, and particle therapy ablation.



FACULTY

Amin Al-Ahmad, MD

Texas Cardiac Arrhythmia Institute Austin, TX

Christine Albert, MD

Cedars Sinai Medical Center Los Angeles, CA

Samuel Asirvatham, MD

Mayo Clinic Rochester, MN

Patricia Blake

Heart Rhythm Society Washington DC

Jared Bunch, MD

University of Utah Salt Lake City, UT

Jie Cheng, MD PhD

Texas Heart Institute Houston, TX

James Cox, MD

Northwestern Medicine Evanston, IL

Thomas Deering, MD

Piedmont Heart Atlanta, GA

Luigi Di Biase, MD, PhD

Montifiore Medical Center New York, NY

Rakesh Gopinathannair, MD, MA

Kansas City Heart Rhythm Institute Overland Park, KS

Christopher Ellis, MD

Vanderbilt University Medical Center Nashville, TN

Benhur Henz, MD

Hospital do Coração do Brasil Brazil

Jodie Hurwitz, MD

North Texas Heart Center Dallas, TX

Suraj Kapa, MD

Mayo Clinic Rochester, MN

Scott Koerber, MD

Kansas City Heart Rhythm Institute Overland Park, KS

Andrew Krahn, MD

University of British Columbia Vancouver, Canada

Fred Kusumoto, MD

Mayo Clinic Jacksonville, FL

Dhanunjaya Lakkireddy, MD

Kansas City Heart Rhythm Institute Overland Park, KS

Luis Leite, MD

Mayo Clinic Rochester MN

Srijoy Mahapatra, MD

University of Minnesota Minneapolis, MN

Moussa Mansour, MD

Massachusetts General Hospital Boston, MA

Joseph Marine, MD

John Hopkins Baltimore, MD

Nassir Marrouche, MD

Tulane University New Orleans, LA

Suneet Mittal, MD

Valley Health System New York, NY

Tachapong Nagaramukos, MD

Phyathai Hospital Bangkok Bangkok, Thailand

Andrea Natale, MD

Texas Cardiac Arrhythmia Institute Austin, TX

Brian Olshansky, MD

University of Iowa Health Iowa City, IA

Douglas Packer, MD

Mayo Clinic Rochester, MN

Peter Park, MD

Kansas City Heart Rhythm Institute Overland Park, KS

Jonathon Piccini, MD

Duke Durham, NC

Jayasaree Pillarisetti, MD

University of Texas — San Antonio San Antonio, TX

Jeanne Poole, MD

University Washington — Seattle Seattle, WA

Krishna Pothineni MD

Kansas City Heart Rhythm Institute Overland Park, KS

Vivek Reddy, MD

Mt. Sinai New York, NY

Matthew Reynolds, MD

Beth Israel Medical Center Boston, MA

Andrea Russo, MD

Cooper University Moorsetown, NJ

Sanjeev Saksena, MD

Robert Wood Johnson Memorial Hospital Warren, NJ

Pasquale Santangeli, MD

University of Pennsylvania Philadelphia, PA

William Sauer, MD

University of Colorado Denver, CO

Poojita Shivamurthy, MD

Kansas City Heart Rhythm Institute Overland Park, KS

Kalyanam Shivkumar, MD

UCLA Cardiac Arrhythmia Center Los Angeles, CA

Usman Siddiqui, MD

Advent Health Celebration
Orlando, FL

Ossuma Wazani, MD

Cleveland Clinic Cleveland, OH

Peter Weiss, MD

Banner Health System Phoenix, AZ

Richard Whitlock, MD

Population Health Research Hamilton Ontario, Canada

SATURDAY & SUNDAY, AUGUST 21-22, 2021 Continuing Medical Education Credit is available. Register at www.kchrs.com

COURSE PROGRAM

SATURDAY AUGUST 21, 2021

9	Session	 ((DVID	in E	lectro	ph	vsio	loav	(M	00	lera	tor	s: C)r.]	[homa:	s D	eerind	۱&	Dr.	Chan	dra '	Vasar	nred	d۷)
						•	,	37	`								1 2	1						1	1

- 8:00 Welcome Dr. Dhanunjaya Lakkireddy
- 8:10 The Big Bold Vision for Electrophysiology A President's Perspective Dr. Fred Kusumoto
- 8:20 COVID Related Cardiac Arrhythmias and Myocarditis Diagnosis, Management and Risk Stratification Dr. Rakesh Gopinathannair
- 8:30 Impact of COVID on Electrophysiology? The Ugly, Bad & Good Dr. Andrea Russo
- 8:40 Panel Discussion

Session II – Electrophysiology Pioneer Award Celebration (Moderator: Dr. Thomas Deering & Dr. Fred Kusumoto)

- 9:00 Pioneer in Cardiovascular Electrophysiology Award Presentation Keynote Speaker: Dr. Douglas Packer
- 9:30 What All Did We Learn from CABANA, EAST AF NET and EARLY AF? Dr. Sanjeev Saksena
- 9:40 Panel Discussion

Session III – Thinking Outside the Box for Heart Failure (Moderators: Dr. Peter Park & Dr. Christine Albert)

- 9:50 Role of Cardiac Contractility and Baroflex Activation Therapy in Managing Patients with Heart Failure Dr. Jodie Hurwitz
- 10:00 The AF-HFpEF Syndrome Role of Rhythm Control Through Catheter Ablation Dr. Sanjeev Saksena
- 10:10 Leadless Left Ventricular Pacing Using Transthoracic Ultrasound Stimulation Dr. Vivek Reddy
- 10:20 Advances in His Bundle Pacing & Left Bundle Pacing Tools, Techniques & Data Dr. Parikshit Sharma
- 10:30 Panel Discussion

Session IV — Prevention & Management of Cardiac Device Infection (Moderators: Dr. Andrew Krahn & Dr. Jodie Hurwitz)

- 10:50 What Are the Barriers to The Identification and Management of Cardiac Device Related Infections? Dr. Jonathan Piccini
- 11:00 Role of Antibiotic Prophylaxis, Pouches, Rinses and Other Techniques in Preventing CIED Infections Dr. Jayasree Pillarisetti
- 11:10 Bacteremia and CIED How Do You Manage an Infected CIED? Dr. Andrew Krahn
- 11:20 Latest in Tools and Techniques for Extraction of Cardiac Devices Dr. Matthew Reynolds
- 11:30 Panel Discussion
- 11:50 Break
- 12:00 Lunch: Non-CME Technology Theatre (Located in non-CME area) Impulse Dynamics, BioSig Technologies, Baylis Medical

Session V – Innovations in AF Management (Moderators: Dr. Andrea Natale & Dr. Samuel Asirvatham)

- 1:00 Role of Rapid Non-Contact Mapping in Understanding and Treating Atrial Arrhythmia Dr. Dhanunjaya Lakkireddy
- 1:10 Insights into Atrial Substrate Through Cardiac MRI and Computational Modeling A Recipe for Enhanced Success Dr. Joseph Marine
- 1:20 What Is the Best Mapping & Ablation Approach for Long Standing Persistent AF? Cooking the Atrium In 3 Different Ways

 Dr. Douglas Packer Dr. Andrea Natale Dr. James Cox
- 1:50 Panel Discussion

Session VI – What Is the Buzz About Pulse Field Ablation? (Moderators: Dr. Srijoy Mahapatra & Dr. Moussa Mansour)

- 2:10 How Exactly Is Pulse Field Ablation Different from Radiofrequency Ablation? Dr. Samuel Asirvatham
- 2:20 What Have We Learnt About the Therapeutic Efficacy of PFA in AF? Dr. Vivek Reddy
- 2:30 Can PFA Deliver on The High Promises of Safety Hope or Hype? Dr. Steve Mickelsen
- 2:40 Novel Technologies in PFA Dr. Moussa Mansour
- 2:50 What Data Needs to Be Generated for PFA to Be Primetime? Dr. Fred Kusumoto
- 3:00 Break

KANSAS CITY HEART RHYTHM SYMPOSIUM 2021

COURSE PROGRAM

Session VII – Improving the Efficiency of Ablation (Moderators: Dr. Jayasree Pillarisetti & Dr. Christine Albert)

- 3:20 Catheter Tip Modification and Impact on Procedural Outcomes QDOT and Flexibility Dr. Andrea Natale
- 3:30 The Science Behind the Indices of Ablation Ablation Index, Lesion Stability Index and All Dr. Tachapong Nagramukos
- 3:40 Left Atrial Scar and Ablation Strategy Personalized Approach in AF Ablation Dr. Nassir Marrouche
- 3:50 Hybrid Ablation Who, When Dr. Christopher Ellis
- 4:00 Role of IV Sotalol in Clinical EP Practice Dr. Peter Park
- 4:10 Role of Focal Triggers and Strategies of Ablation Dr. Usman Siddiqui
- 4:20 Panel Discussion

Session VIII – Myocardial Inflammation and Electrophysiology (Moderators: Dr. Luis Leite & Dr. Pasquale Santangeli)

- 4:30 Myocarditis, Arrhythmias and Sudden Cardiac Death Understanding the Connection Dr. Dhanunjaya Lakkireddy
- 4:40 Non-Ischemic Cardiomyopathy and Myocardial Inflammation An Evolving Paradigm Dr. Jeanne Poole
- 4:50 Diagnostic and Management Strategies for Arrhythmogenic Myocarditis Dr. Kalyanam Shivkumar
- 5:00 Risk Stratification for SCD in Patients with Infiltrative and Inflammatory Cardiomyopathies Dr. William Sauer
- 5:10 Role of Pacing Therapies in Treating Central and Obstructive Sleep Apnea Respicardia, Inspire & More Dr. Sanjaya Gupta
- 5:20 Panel Discussion

SUNDAY, AUGUST 22, 2021

Session IX – Stroke Prophylaxis and Left Atrial Appendage Management (Moderators: Dr. Jonathan Piccini & Dr. Krishna Pothineni)

- 8:00 Heart Rhythm Society Navigating a Global Pandemic and Serving the Needs of the Members Ms. Patricia Blake
- 8:10 What Did We Learn from LAAOS-3? Role of LAA Exclusion in Stroke Prophylaxis Dr. Richard Whitlock
- 8:20 Stroke Prophylaxis and LAA Endocardial Occluders Where Are We Today? Dr. Jared Bunch
- 8:30 Role of LAA in Arrhythmogenesis and Management Strategies and Pitfalls Dr. Suneet Mittal
- 8:40 LAA Closure After Successful AF Ablation Can It Mitigate the Need for Continued Oral Anticoagulation? Dr. Oussama Wazni
- 8:50 Closure Options for Unusual LAA Anatomies Dr. Luigi Di Biase

Session X – Digital Health in Electrophysiology (Moderators: Dr. Jeanne Poole & Dr. Scott Koerber)

- 9:00 Define AF Managing AF Through Implantable Cardiac Monitors in The Digital Playground Dr. Andrea Russo
- 9:10 Smart Watches and Wearable External Heart Rhythm Monitors Where Do They Fit in The EP Practice? Dr. Christine Albert
- 9:20 Machine Learning in Optimizing Electrophysiology Procedures How Far Have We Come? Dr. Suraj Kapa
- 9:30 Digital Health Tools That Can Optimize the Care of Patients in The Outpatient Setting Dr. Thomas Deering
- 9:40 Panel Discussion
- 10:00 **Break**

Section XI – Managing Ventricular Arrhythmias (Moderators: Dr. Benhur Henz & Dr. Sanjeev Saksena)

- 10:10 What Is the Most Practical Approach to Performing VT Ablation? Dr. Kalyanam Shivkumar
- 10:20 Role of Remote Magnetic Navigation in VT Ablation Dr. Peter Weiss
- 10:30 Bipolar ablation for difficult PVC/VT ablation? Dr. Piotr Futyma
- 10:40 How to Improve Success Rates of a Summit and Papillary Muscle PVC Ablation? Dr. Pasquale Santangeli
- 10:50 Panel Discussion

Session XII – What Is the Incremental Benefit of Additional Tools (Moderators: Drs Luigi Di Biase & Dr. Poojitha Shivamurthy)

- 11:10 Vascular Closure Devices for EP Procedures Clinical & Cost Effectiveness Data Dr. Amin Al-Ahmad
- 11:20 Esophageal Temperature Monitoring Stethoscope, Circa, Infrared or Single Tip Thermocouple Probe? Dr. William Sauer
- 11:30 Safety and Efficacy of Esophageal Deviation During AF Ablation Dr. Jie Cheng
- 11:40 RF Transseptal Needle in EP and Structural Procedures Varied Choices and Applications Dr. Amin Al-Ahmad
- 11:50 Pacing in Vasovagal Syncope Dr. Brian Olshansky
- 12:00 Panel Discussion
- 12:20 **Closing Remarks** Dr. Dhanunjaya Lakkireddy





At the conclusion of this activity, participants should be able to:

- Discuss types of devices used for monitoring and treating arrhythmias
- Demonstrate the use of imaging techniques to improve procedural outcomes
- Apply guideline-endorsed, clinically applicable strategies to help resolve device-related issues
- Summarize clinical trial results that can be applied to improving the safety and efficacy of electrophysiology (EP) procedures
- Explain anticoagulation treatment and stroke prophylaxis options for cardiac patients
- Examine clinical evidence for the latest trends in LAA treatments

METHOD OF PARTICIPATION

How to obtain CME credit:

- 1. Go to www.ACHLcme.org
- 2. Click on "Use Certificate Code"
- 3. Enter the Certificate Code 4408907
- **4.** Complete the evaluation, and your certificate will be immediately available to you.

Participants will receive an automated certificate. You may print or save this record for your files. It will also be sent to you via email to the address provided in your profile on www.ACHLcme.org. There is no fee for the generation of the certificate.

Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and the Kansas City Heart Rhythm Symposium (KCHRS). The Academy for Continued Healthcare Learning is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians: ACHL designates this live activity for a maximum of 13.00 *AMA PRA Category 1 Credits* ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: Provider approved by the California Board of Registered Nursing, Provider Number CEP17273 for 13.00 contact hours. For questions about the CME/CE accreditation of this activity, please contact ACHL at 773-714-0705 x160 or mstradal@achlcme.org.

DISCLOSURES

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. For a full listing of faculty disclosures, please access www.kchrs.com

ACHL staff members, Kansas City Heart Rhythm Symposium staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

DISCLAIMER

The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

ACKNOWLEDGEMENTS

COMMERCIAL SUPPORTERS

This symposium is supported through educational grants from

Abbott
Acutus Medical, Inc.
Biosense Webster, Inc.

BioTelemetry, Inc.
BIOTRONIK, Inc.
Boston Scientific Corporation
CVRx Barostim

Medtronic
Philips Medical
ZOLL Medical

EXHIBITORS

We wish to acknowledge and sincerely thank the following organizations for exhibiting.

PREMIERE TIER

Abbott
AtriCure, Inc.
Baylis Medical
Biosense Webster
BIOTRONIK, Inc.
Boston Scientific Corporation
Medtronic

AltaThera Pharmaceuticals, LLC
BioSig Technologies, Inc.
Bristol Myers Squibb
Circa Scientific, Inc.
CVRx Barostim
EBR Systems
EPreward, Inc.
Impulse Dynamics

Irrimax Corporation
Janssen
Novartis Pharmaceuticals
Philips BioTel Heart
Philips Image Guided Therapy Devices
Preventice Solutions
Stereotaxis
Zoll LifeVest
Kansas City Heart Rhythm Institute

OTHER SPONSORSHIPS

Zio by iRhythm

We wish to acknowledge and sincerely thank the following organizations for holding Technology Theatres

Impulse Dynamics

BioSig Technologies, Inc.

Baylis Medical

NON-PROFIT ORGANIZATIONS

EP Live Foundation Global Atrial Fibrillation Alliance (GAFA) International Symposium on Left Atrial Appendage (ISLAA)

Journal of Atrial Fibrillation (JAFIB)


STANDARD TIER



AtriCure

Benefits of Hybrid AF™ Therapy

Based on 7-day continuous rhythm monitoring at 18-months post procedure



Visit HybridAFTherapy.com to learn more about Hybrid AF Therapy for the treatment of long-standing persistent atrial fibrillation.





EFFICIENT EXCHANGELESS EFFORTLESS with the

VersaCross®

RF Transseptal Solution





Left atrial appendage closure




Cryoba**ll**oon procedures



RF Ablation

FASTTRACK access-to-delivery of left heart therapy devices

PRM-00797 EN J-1,2,3 V-1 © Copyright Baylis Medical Company Inc., 2021. Baylis Medical Company Inc., reserves the right to change specifications or to incorporate design changes without notice and without incurring an obligation relating to equipment previously manufactured or delivered. VersaCross, the VersaCross logo, Baylis Medical and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. it the USA and/or other countries. Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for use.







EARLIER ABLATION FOR ATRIAL FIBRILLATION

EARLIER RESTORATION OF SINUS RHYTHM BY CATHETER ABLATION IN PATIENTS WITH ATRIAL FIBRILLATION (AFIB) MAY REDUCE PATIENT MORBIDITY AND DISEASE PROGRESSION, IMPROVE LONG-TERM PROCEDURAL SUCCESS, AND LOWER OVERALL PATIENT MORTALITY.¹⁻³

Patients who have longer diagnosis-to-ablation times (DAT) experience higher rates of transient ischemic attacks, stroke and heart failure, as compared to patients who receive ablation earlier. ^{4,5}



In a prospective registry of 1000 AFib patients, patients receiving ablation with a shorter DAT had a 60% lower rate of TIA/CVA events compared to patients with a longer DAT.⁵

*Relative reduction from the comparison of 244 patients with DAT of \leq 11 months versus 250 patients with a DAT of \geq 71 months at 5 year follow-up. TIA/CVA were defined as a transient or persistent neurological deficit diagnosed by a neurologist. Differences were significant where p<0.001.




In registry study of 4535 AFib patients, patients with the shortest DAT had 41% lower rates of heart failure hospitalization at one year as compared to patients with the longest DAT. 4

*Relative reduction from the comparison of 1152 patients with a DAT of 1-6 months versus 1201 patients with a DAT of >5 years at a mean follow-up for 3.2 years. Heart failure hospitalization defined as ICD-9 code 428 within patient EMR. Differences were significant where p-trend=0.009.

Early treatment of AFib with catheter ablation substantially reduces the rate of AFib progression from paroxsymal AFib to persistent AFib, a more complex and difficult to treat disease state.²

The ATTEST randomized controlled trial found that paroxysmal AFib patients receiving ablation are up to **10 times less likely to progress to persistent AFib**, compared to those treated with anti-arrhythmic drugs.²

Difference statistically significant (HR: 0.114)



BIOTRONIK

Premium Product Portfolio












	Pacemakers	Defibrillators	CRT-Ds	CRT-Ps	Diagnostics		
MRI Capabilities	Full body 1.5/3.0 T Single/Dual	Full body 1.5/3.0 T DX/Dual DF1 & DF4	Full body 1.5/3.0 T DF1 & DF4	Full body 1.5/3.0 T IS1/IS4	Full body 1.5/3.0 T		
Home Monitoring	Automatic, daily, including HF trends, online alert programmability.	Automatic, daily, including HF trends, online alert programmability.	Automatic, daily, including HF trends, online alert programmability.	Automatic, daily, including HF trends, online alert programmability.	Automatic, daily, including HF trends, online alert programmability.		
Rate Response	Accelerometer Closed Loop Stimulation	Accelerometer Closed Loop Stimulation	Accelerometer Closed Loop Stimulation	Accelerometer Closed Loop Stimulation			
Effective Therapies	I-Opt; Vp Supression	DX Technology Ultra High Energy	CRT AutoAdapt, LV Polarites Management with 20 polarities, IN-TIME Template, Quick Check	I-Opt; Vp Supression			

Vascular Intervention





- Improved patient outcomes¹
- Only ultrathin DES in the US²
 Excellent deliverablity, with lowest crossing profile³ and up to 72% more force from hub to tip³



PK Papyrus**

- The only 5 F compatible⁴ covered coronary stent available in the US
 First FDA approved 2.5 mm diameter covered coronary stent⁵
 Designed to deliver more like a conventional stent^{6,7}



PRO-Kinetic Energy

- Thinnest struts-period
- Exceptional deliverability • Best-in-class clinical data



Pantera Pro & Pantera LEO

Workhorse and Non-Compliant Balloons



Galeo Pro

Family of high-tensile stainless steel Guide Wires

Partner Alliances



Zero-Gravity®

Suspended radiation protection system designed to increase the level of radiation protection while at the same time eliminating the weight burden for the operator

BIOTRONIK, Inc. 6024 Jean Road Lake Oswego, OR 97035-5369 [800] 547-0394 [24-hour] (800) 291-0470 (fax) www.biotronik.com © 2021 BIOTRONIK, Inc. All rights reserved. BR263r11 11/15/19

*Animal model. **Humanitarian Device. Authorized by Federal law for use in the treatment of acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter. The effectiveness of this device for this use has not been demonstrated.


1. Kandzari D et al. JAm Coll Cardiol. 2018, 72(25). 2. When compared to FDA approved Drug Eluting Stents. BIOTRONIK data on file; 1. BIOTRONIK data on file; 1. BIPIP24/2018. 4. For 2.5-4.0 mm diameter compared to Graftmaster; 6F compatible for 4.5-5.0 mm 5. FDA Humanitarian Device Exemption [HDE] Database: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfHDE/fAde.cfm; last accessed September 14, 2018 6. Compared to Graftmaster 2.8/16 [BIOTRONIK data on file]





ACCURACY MATTERS SEE THINGS DIFFERENTLY

ADVISOR™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FAST.¹ ACCURATE.² EASY-TO-USE.³







THE LEADER IN LAAC THERAPY

Advance Safety | Advance Procedural Performance | Expand the Treatable Patient Population

Built on the most studied and implanted LAAC device in the world, WATCHMAN FLX is designed to advance procedural performance and safety while expanding the treatable patient population.

See the Difference watchman.com/implanter

Please review safety and indication information at watchman.com/implanter. ©2021 Boston Scientific Corporation or its affiliates.

All rights reserved. All trademarks are property of their respective owners. SH-1004603-AA



THEY SAY PROBLEMS ARE JUST OPPORTUNITIES IN DISGUISE

That's why we work tirelessly to find solutions.

More than 60 years ago, our founder created the first battery-operated pacemaker, so cardiac patients wouldn't have to depend on electricity. And recently, we developed the first hybrid closed-loop insulin pump to help people with diabetes gain greater freedom while managing their glucose levels.

Problem solving. It's what we do.

That's why, in addition to devices, our work today includes things like:

- Enabling the early detection and treatment of a variety of conditions
- Lowering post-hospitalization complication rates
- Optimizing hospital and clinic efficiency

LET'S FIND OPPORTUNITIES — TOGETHER.

medtronic.com/ transforminghealthcare





March 4 - 5, 2022 Los Angeles, CA

COURSE DIRECTORS

Dhanunjaya Lakkireddy, MD, FACC, FHRS Kansas City Heart Rhythm Institute - Overland Park, KS

Andrea Natale, MD, FACC, FHRS, FESC Texas Cardiac Arrhythmia Institute - Austin, TX David R. Holmes, MD, FACC, FSCAI Mayo Clinic, Rochester, MN

Vivek Reddy, MD Mount Sinai Hospital - New York, NY Saibal Kar, MD, FACC, FHRS, FESC Los Robles Medical Center - Los Robles, CA

TARGET AUDIENCE

The 10th International Symposium on Left Atrial Appendage strives to serve as the premier educational event for electrophysiologists, interventional cardiologists, neurologists and stroke specialists, internal and family medicine physicians and associated professionals dedicated to the management of patients with arrhythmias.

COURSE OVERVIEW

This symposium updates you on everything you need to understand about stroke prevention and Left Atrial Appendage (LAA) exlusion procedures.

Highlights Include:

- Anatomy and physiology of LAA
- Stroke pathophysiology and the role of LAA
- · Clinical issues related to LAA exlusion
- Clinical trials on LAA exlusion devices
- Anticoagulation strategies

- Live Case Telecast
- Interesting cases
- Panel discussions
- Debates by experts in the field

www.islaasymposium.com